Chiron, Ribozyme deal

The companies agreed to use RZYM's technology to probe the function of several gene sequences selected by CHIR. RZYM will design and synthesize ribozymes that selectively inhibit the action of the target sequences in CHIR's assays. CHIR receives the option to develop ribozymes or other products against sequences found to be important in disease pathology.

In addition to research support, RZYM is eligible for milestones that could total $80 million. RZYM also receives ribozyme manufacturing rights, and will receive royalties. ...